NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

But its nonsense. NWBO or any other biotech would not go through all this trouble to have a trial failure published in any journal.

In the glioblastoma space:

CLDX's Rindopepimut P3 published in the Lancet, failed trial, over 100 authors.

Louristine and teh drug formerly known as Aviston published in NEJM. Failed P3 in rGBM, 27 authors.

I could easily find more.

What you will not find an example of is a P3 in the setting that did not publish.